LON:STX Shield Therapeutics (STX) Share Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free STX Stock Alerts GBX 1.23 -0.10 (-7.55%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range 1.06▼ 1.3150-Day Range 1.31▼ 5.8552-Week Range 1.06▼ 12.85Volume8.92 million shsAverage Volume5.15 million shsMarket Capitalization£9.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Shield Therapeutics alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About Shield Therapeutics Stock (LON:STX)Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.Read More STX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STX Stock News HeadlinesApril 10, 2024 | msn.comNeutral Switzerland joins European Sky Shield defence projectApril 1, 2024 | tmcnet.comAmerican Home Shield Offering 40% Off ShieldGold™ For Limited TimeApril 25, 2024 | DTI (Ad)What is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…March 29, 2024 | msn.comA Real Life Invisibility Shield for Privacy in Public PlacesMarch 11, 2024 | tmcnet.comSeal Shield to Showcase Shyld AI, the World's First Intelligent, Autonomous, UV-C Disinfection System at HIMSS 2024February 23, 2024 | lse.co.ukLONDON MARKET CLOSE: FTSE 100 takes hit ahead of FOMC minutesFebruary 22, 2024 | morningstar.comShield Therapeutics PLC STXFebruary 13, 2024 | uk.finance.yahoo.comShield Therapeutics plc (STX.L)April 25, 2024 | DTI (Ad)What is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…January 24, 2024 | finance.yahoo.comShield Therapeutics (LON:STX) shareholders have endured a 89% loss from investing in the stock three years agoDecember 28, 2023 | finance.yahoo.comShield Therapeutics plc (LON:STX) Is Expected To Breakeven In The Near FutureOctober 20, 2023 | proactiveinvestors.comShield Therapeutics to present at NPWH conference this monthOctober 12, 2023 | marketwatch.comShield Therapeutics CFO Hans-Peter Rudolf to Step DownOctober 12, 2023 | proactiveinvestors.comShield Therapeutics launches executive search process as CFO steps downOctober 5, 2023 | finance.yahoo.comShield Therapeutics "couldn't be more pleased" with Viatris collaborationOctober 5, 2023 | finance.yahoo.comShield Therapeutics' pricing will be "key metric" - Proactive Research AnalystOctober 3, 2023 | proactiveinvestors.comShield Therapeutics secures debt facility, retail share offer closes soonSeptember 30, 2023 | finance.yahoo.comShield Therapeutics First Half 2023 Earnings: US$0.025 loss per share (vs US$0.069 loss in 1H 2022)September 29, 2023 | msn.comShield Therapeutics hails progress in Stateside venture as losses narrowSeptember 28, 2023 | marketwatch.comShield Therapeutics Shares Fall After Discounted Equity RaiseSeptember 5, 2023 | finance.yahoo.comPrivate companies who hold 41% of Shield Therapeutics plc (LON:STX) gained 17%, institutions profited as wellJuly 29, 2023 | proactiveinvestors.comShield Therapeutics : First signs of hoped-for Accrufer Rx inflectionJuly 25, 2023 | finanznachrichten.deHardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gatheringJuly 25, 2023 | finance.yahoo.comShield Therapeutics "really starting to fire on all cylinders"July 20, 2023 | marketwatch.comShield Therapeutics Shares Rise as US Prescriptions for Accrufer SoarJuly 20, 2023 | msn.comShield Therapeutics makes waves in US as iron deficiency prescriptions ramp upJuly 20, 2023 | proactiveinvestors.comShield Therapeutics reports 173% Accrufer prescription growthSee More Headlines Receive STX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:STX CUSIPN/A CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500FaxN/AEmployees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.12) Trailing P/E RatioN/A Forward P/E Ratio53.36 P/E GrowthN/ANet Income£-48,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-146.62% Return on Assets-42.79% Debt Debt-to-Equity Ratio21.30 Current Ratio2.95 Quick Ratio2.16 Sales & Book Value Annual Sales£7.40 million Price / Sales1.32 Cash FlowGBX 0.20 per share Price / Cash Flow6.36 Book ValueGBX 4 per share Price / Book0.31Miscellaneous Outstanding Shares782,060,000Free FloatN/AMarket Cap£9.74 million OptionableNot Optionable Beta0.84 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Gregory P. Madison (Age 57)CEO & Executive Director Comp: $678kDr. Christian Schweiger M.D. (Age 58)Ph.D., Co-Founder & Non Executive Director Comp: $45kMr. Santosh Shanbhag (Age 46)Chief Financial Officer Ms. Lucy Kate Huntington-BaileyGeneral Counsel & Company SecretaryMs. Suzanne WoodGroup HR DirectorMs. Carol AkinolaHead of Pharmacovigilance & Medical InformationMr. Andrew Hurley (Age 55)Chief Commercial Officer Kate ArmanettiSenior Director of People & CultureMore ExecutivesKey CompetitorsChill Brands GroupLON:CHLLArgent BioPharmaLON:MXCProvexisLON:PXSHellenic DynamicsLON:HELDInduction Healthcare GroupLON:INHCView All Competitors STX Stock Analysis - Frequently Asked Questions How have STX shares performed in 2024? Shield Therapeutics' stock was trading at GBX 6.70 on January 1st, 2024. Since then, STX stock has decreased by 81.7% and is now trading at GBX 1.23. View the best growth stocks for 2024 here. What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and SkinBioTherapeutics (SBTX). How do I buy shares of Shield Therapeutics? Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:STX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
